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ABSTRACT:

Melanoma-associated vitiligo is the best-studied example of the linkage between
tumor immunity and autoimmunity. Although vitiligo is an independent positive
prognostic factor for melanoma patients, the autoimmune destruction of melanocytes
was long thought to be merely a side effect of robust anti-tumor immunity. However,
new data reveal a key role for vitiligo in supporting T cell responses to melanoma. This
research perspective reviews the history of melanoma-associated vitiligo in patients,
the experimental studies that form the basis for understanding this relationship,
and the unique characteristics of melanoma-specific CD8 T cells found in hosts with
vitiligo. We also discuss the implications of our recent findings for the interpretation
of patient responses, and the design of next-generation cancer immunotherapies.

INTRODUCTION

MELANOMA AND VITILIGO:
A HISTORY OF CLINICAL
CORRELATIONS

The past several decades of research in tumor
immunology have revealed a strong link between
tumor immunity and autoimmunity. This connection is
first understood in the context of the extensive overlap
between antigens expressed by a tumor and its normal
tissue counterpart [1, 2]. The best-studied example of
concurrent tumor immunity and autoimmunity is the
development of vitiligo in association with melanoma.
Vitiligo, or the autoimmune destruction of melanocytes,
is an independent positive prognostic factor for melanoma
patients [3-5], and its incidence is increased by certain
immunotherapies that drive T cell responses to melanoma
[6-8]. For years, autoimmunity has been viewed as a
side effect of robust anti-tumor immunity. New research
now demonstrates that autoimmune melanocyte killing
also directly maintains T cell immunity to melanoma
[9]. The crucial role of autoimmunity in shaping antitumor immunity now informs the interpretation of
immunotherapeutic responses in the lab and in the clinic.
In this research perspective, we explore the history linking
melanoma and vitiligo in patients, key experiments in
animal models that have shaped our understanding of
this relationship, and the characteristics of memory T
cell responses that are governed by vitiligo. Finally, we
discuss the importance of autoimmunity for the success
of tumor immunotherapy.
www.impactjournals.com/oncotarget

Melanoma and vitiligo, despite diametrically
opposed clinical manifestations, have been empirically
linked for over 50 years with significant implications
for patients. Melanoma, the outgrowth of transformed
melanocytes, has long been recognized as a particularly
aggressive cancer, with median survival for metastatic
disease ranging between 6-11 months [10, 11]. Surgical
treatment has been the standard of care for nearly 150
years [12]. One of the earliest case-based observations
linking vitiligo and melanoma was published in 1953,
when a patient with a ‘melanosarcoma’ developed
depigmented lesions [13], followed by a report in 1960
noting systemic depigmentation in a melanoma patient
treated with radiation therapy [14]. Four years later,
Burdick and Hawk reported regression of cutaneous and
visceral lesions – concurrent with the development of
vitiligo – in a metastatic melanoma patient treated with
Vaccinia virus [15]. The following year, Smith and Sehlin
reported the development of vitiligo in several melanoma
patients with spontaneously regressing primary tumors
[16]. These papers were among the first to suggest that
tumor immunity and autoimmunity were linked.
Beginning in the early 1970’s, studies began to
684
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suggest that vitiligo portended improved prognosis for
melanoma patients. A small study of 11 patients reported
that survival was slightly prolonged in metastatic melanoma
patients with vitiligo, but concluded that data supporting a
‘direct relationship between the two conditions’ was still
lacking [17]. Several case studies continued to comment
on the association between vitiligo and enhanced survival
in melanoma patients, but without statistical support [1820]. It wasn’t until 1983 that Nordlund and colleagues
demonstrated significantly enhanced 5-year survival rates
in melanoma patients with vitiligo [3]. This was followed
by a more extensive study by Bystryn and colleagues in
1987, which reached similar conclusions [4]. However,
these studies included a majority of patients with Stage I
or II disease, and data from metastatic melanoma patients
was lacking. Recently, in a large cohort of metastatic
melanoma patients, Quaglino and colleagues reported
that vitiligo was an independent positive prognostic factor
correlating with significantly enhanced 5-year survival,
providing further support for long-reported clinical
observations [5]. Thus vitiligo is clearly associated with
improved immunity to melanoma in patients, though the
mechanisms linking these phenomena remain a subject of
active investigation.

of differentiation antigens that are shared by normal
melanocytes [1, 27]. This family of proteins includes
tyrosinase and related proteins TRP-1 (gp75) and TRP-2
(dopachrome tautomerase), as well as gp100, and MART1 (Melan-A); each of which plays a critical role in melanin
synthesis [2]. Melanocyte differentiation antigens have
since formed the basis for analyzing antigen-specific
immune responses to both melanoma and melanocytes
[28].
Currently, there are two major proposed mechanisms
of vitiligo pathogenesis; one antibody based, and the other
T cell based [29]. Autoantibodies recognizing tyrosinase,
TRP-1, and TRP-2, have been detected in the sera of
melanoma patients and vitiligo patients [30]. The total
levels of antibodies directed against pigmented cells have
also been shown to correlate with the extent of vitiligo
in melanoma-free patients [31]. Additionally, antibodies
found in the sera of vitiligo patients have been shown
to lyse melanocytes and melanoma cells in vitro [32].
However, data supporting antibody-mediated vitiligo in
melanoma patients have been limited. Compared with
vitiligo patients, melanoma patients with vitiligo have
been shown to have similar titers of antibodies to TRP2 [33], although they have significantly lower titers of
antibodies directed against whole melanoma cells and
tyrosinase [34, 35].
On the other hand, there is substantial evidence that
CD8 T cells mediate melanoma-associated vitiligo. CD8
T cells taken from lesions of vitiligo patients have been
shown to kill melanoma cells ex vivo [36], and CD8 T
cells from both tumors and peripheral blood of melanoma
patients have been shown to kill normal melanocytes
[37]. In melanoma patients with vitiligo, clonotypically
identical T cells were found in both the tumor and
surrounding depigmented lesions [38]. It has been shown
that the majority of cells infiltrating these lesions are
CD8+ T cells that recognize both normal melanocytes and
melanoma cells [39]. Accordingly, after therapeutically
transferring MART-1 specific CD8 T cells to a melanoma
patient, transferred cells were found to accumulate in
depigmented lesions that developed as a result of therapy
[40]. CD4 T cells have also been found to infiltrate vitiligo
lesions, although less is known about melanocyte-specific
CD4 T cell responses [36, 41]. Two recent studies have
identified increased levels of IL-17 in both the serum and
tissue of vitiligo patients [42, 43], which may suggest
CD4 T cell involvement. Therefore significant clinical
evidence supports the theory that melanoma-associated
vitiligo is a CD8 T cell mediated phenomenon, although
antibodies and/or CD4 T cells may also play roles.

MECHANISMS
OF
MELANOMAASSOCIATED VITILIGO IN HUMANS
As the correlative relationship between vitiligo and
melanoma was beginning to be described, the role of the
immune response in melanocyte destruction was also
under investigation. In 1971, Milton et al. argued that
spontaneous regressions of primary melanomas implied
active anti-tumor immunity, and suggested that associated
vitiligo was also a manifestation of this immune response
[17]. Supporting this argument, lymphocytic infiltrates
were observed in melanomas of several vitiligo-affected
patients that underwent spontaneous regression [16, 21].
The infiltration of lymphocytes into both melanoma and
vitiligo lesions, as well as spontaneous regression of
primary melanoma tumors [16], led to the hypothesis in
1971 that depigmentation was immune-mediated [17]. Over
the next decade, several groups postulated the ‘tempting’
idea that melanoma-associated vitiligo was the result of
a cross-reactive immune response [3, 22, 23]. However,
early studies conceded that other non-immunological
mechanisms may be in play, and alternatives to immune
mediated pathology were postulated [24]. Theories
suggested that toxins from nerves, free radical scavenging,
or byproducts from melanin manufacturing itself resulted
in the death of melanocytes or the disabling of melanin
production [25, 26].
Today, overwhelming genetic and immunologic
evidence supports the autoimmune etiology of vitiligo in
melanoma patients. Studies by Houghton et al. in the early
1980’s revealed that melanoma cells express a family
www.impactjournals.com/oncotarget

LESSONS LEARNED FROM ANIMAL
MODELS
Concurrent with these efforts to understand the
relationship between melanoma and vitiligo in the clinic,
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a wealth of mechanistic studies has been undertaken in
the laboratory. Inbred C57BL/6 mice and the syngeneic,
transplantable, B16 mouse melanoma model have
greatly facilitated this work. Hara et al. were the first to
report the outgrowth of white hair in black mice upon
treatment with the TA99 monoclonal antibody to TRP1 [44]. Mice treated with TA99 were also protected
against B16 melanoma, showing for the first time that
immune responses against shared melanoma/melanocyte
antigens could concurrently mediate tumor immunity
and autoimmunity [44]. Since this seminal work, studies
have turned largely to inducing CD8 T cell responses, and
several MHC I-restricted epitopes from gp100 [45], TRP2 [46], tyrosinase [47], and TRP-1 [48] have since been
employed as targets of melanoma vaccines and cellular
therapies. T cell receptor transgenic mice with specificity
for melanocyte antigens have also provided a valuable
tool for understanding mechanisms driving rejection of
established melanoma and the induction of vitiligo [4952]. Below we discuss the experiments in mice that have
most contributed to our understanding of tumor immunity
and concomitant autoimmunity.

administration of altered melanocyte antigens has been
one strategy used to overcome tolerance. DNA vaccines
encoding altered forms of melanocyte differentiation
antigens, such as xenogenic gp100 [53, 54], epitope
enriched TRP-1 [48], and randomly mutated TRP-2
[55], have each proven effective at priming CD8 T cell
responses, resulting in protective immunity against
melanoma and concomitant vitiligo. Altered self-antigens
have also been highly effective when administered in the
context of viral vaccine vectors [56], or as heteroclitic
peptides in combination with multifactorial adjuvants
such as anti-CD40 and TLR agonists [57, 58].
Other studies have shown that altered antigen is
not required to break tolerance to melanocyte antigens
if sufficient inflammatory and/or costimulatory signals
are present. For example, irradiated B16 tumor cells
producing GM-CSF (GVAX) combined with a blocking
monoclonal antibody to CTLA-4 breaks tolerance to
melanocyte differentation antigens, resulting in protective
anti-tumor immunity and vitiligo [59]. Treatment with
monobenzone, a compound which results in melanocyte
killing through haptenization of tyrosinase and induction
of melanocyte autophagy [60], also leads to rejection of
B16 melanoma tumors and the development of vitiligo
when combined with TLR agonists [61]. Lymphopeniainduced homeostatic T cell proliferation in the context of
a progressive melanoma, and the absence of CD4+CD25+
regulatory T cells (Treg), is sufficient to break tolerance
and induce vitiligo, likely due to the removal of both
suppression and homeostatic cytokine sinks [62]. Thus,
inflammatory, costimulatory, and/or cytokine stimuli may
be sufficient to break tolerance to antigens expressed by
melanoma cells or dying melanocytes.
Further, our own work has shown that, even in the
absence of overt inflammatory stimuli, disruption of
regulatory T cell-mediated suppression is sufficient to
overcome tolerance to melanoma-expressed self-antigens.
In B16 tumor-bearing mice, we found that depletion of
Treg cells by treatment with anti-CD4 breaks CD8 T
cell tolerance to TRP-2 and gp100 [63]. These tumorprimed CD8 T cells, although unable to control growth
of established primary B16 melanoma tumors, provide
systemic concomitant immunity against B16 re-challenge
[63]. Furthermore, following Treg depletion, we showed
that surgical excision of intradermal B16 melanoma
tumors resulted in a majority of mice developing CD8 T
cell-mediated vitiligo [9, 63]. Interestingly, trauma to the
skin has previously been shown to provide non-specific
inflammation that is critical for vitiligo induction [56,
64]. Whereas surgical tumor excision was employed in
our model as a means for prolonging host survival, it may
also play a role in initiating vitiligo. In fact, we typically
observe vitiligo first at the site of surgery [9], often
in a pattern that mimics the incision site with striking
accuracy (Figure 1). Taken together, these studies indicate
the existence of multiple pathways for overcoming T

Primary T cell responses to melanoma and
melanocytes
The major focus of melanoma immunotherapy
over the past 20 years has been on breaking T cell
tolerance to melanocyte differentiation antigens, and
vitiligo is a common occurrence with such therapies. The

Figure 1: Vitiligo initiation at site of surgery. Mice

bearing intradermal B16 tumors on the right flank were treated
by anti-CD4 monoclonal antibody to deplete regulatory T cells,
followed by surgical tumor excision, as we have previously
described [63]. 3 weeks after surgery, vitiligo was observed
along the surgical incision line (dotted line), and at points where
surgical clips had pierced the skin (arrows).
www.impactjournals.com/oncotarget
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Maintenance of memory T cell responses to
melanoma and melanocytes

cell tolerance to melanoma and inducing autoimmunity
against melanocytes.
In recent years, T cell receptor transgenic (TCR
Tg) mouse models have provided crucial new insights
into mechanisms driving vitiligo and effective melanoma
immunotherapy. The pmel-1 CD8 TCR Tg mouse was the
first such model, possessing a TCR specific for gp10025-33 in
the context of Db [49]. The pmel T cell clone was originally
raised by vaccination of wild-type (gp100-sufficient) mice
with human gp100, and therefore is thought to have low to
moderate avidity [49]. Pmel mice begin to develop mild,
spontaneous vitiligo at ~10 weeks of age (KTB and MJT,
unpublished observations). Moreover, adoptive transfer of
in vitro activated pmel cells in conjunction with human
gp100 viral vaccination, lymphodepletion, high dose IL2, and/or TLR stimulation induces profound vitiligo and
regression of established melanoma in recipient mice [49,
65-67].
In addition to pmel mice, a TRP-2 specific TCR
Tg mouse with specificity for TRP-2180-188 (termed Clone
37) was more recently generated [50]. These mice do not
develop spontaneous vitiligo, and adoptive transfer of
naïve Tg T cells fails to induce rejection of established
B16 tumors [50]. The low potency of these cells may
be a reflection of a lower avidity TCR, as Clone 37 was
originally raised by vaccination of wild-type mice with
murine TRP-2 [50]. A third model with specificity for
Tyr369-377 in the context of HLA-A2.1 expresses the TCR
from a CD8 T cell clone that was isolated following
vaccination of albino (tyrosinase-deficient) HLA-A2.1
transgenic mice [68, 69]. In contrast to pmel and Clone
37 mice, Tyr369-377 TCR Tg mice develop robust vitiligo,
with symptoms and kinetics similar to human disease,
suggesting that they possess a higher avidity TCR [68].
Interestingly, high-avidity CD4 T cells are also
capable of mediating vitiligo, which may relate to the fact
that both melanocytes and melanoma cells can express
MHC II molecules [70, 71]. A CD4 TCR Tg model with
specificity for TRP-1113-127 was developed from immunized
TRP-1-/- mice [52]. In a wild-type (TRP-1 sufficient)
background, TCR transgene expression results in T
cell activation and vitiligo development [72], however,
these T cells remain naïve on a TRP-1-/- background
[52]. Adoptive transfers of low numbers of naïve TRP1-specific T cells into wild-type mice results in overt
vitiligo and potent rejection of established B16 melanoma
when given in combination with vaccine and IL-2 [52],
irradiation and anti-CTLA-4 [73], or in lymphopenic hosts
[72]. Taken together, these TCR Tg models suggest that
the development of spontaneous vitiligo in unmanipulated
hosts may be dependent on TCR avidity for self-peptide/
MHC. These models have proven to be valuable tools for
understanding the mechanisms behind effective melanoma
adoptive T cell therapy.

www.impactjournals.com/oncotarget

Although generating robust primary CD8 T
cell responses to melanoma has been a subject of
intense investigation, less emphasis has been placed
on understanding the maintenance of T cell memory,
particularly in the context of autoimmune disease.
Studies have demonstrated a correlation between longlived protection against melanoma and depigmentation
in experimental models [49, 63, 65, 67], although
vitiligo-affected and unaffected mice had not been
directly compared with regards to the quality of CD8 T
cell memory. Furthermore, whereas the most effective
immunotherapies against established B16 tumors clearly
generate vitiligo [49, 73], it has remained uncertain
whether autoimmunity confers long-term benefits for antitumor immunity. Research in our laboratory demonstrated
that mice treated by regulatory T cell depletion developed
post-surgical CD8 T cell memory responses to TRP-2 and
gp100 [63]. Because approximately half of these mice
developed vitiligo, this model has enabled investigation
of the unique features of T cell memory in hosts with
concomitant autoimmunity.
Our recent studies reveal that CD8 memory T cells in
vitiligo-affected hosts are potent anti-tumor effectors with
key defining characteristics. First, vitiligo-affected hosts
maintained gp100 and TRP-2-specific memory CD8 T cells
at 10-fold larger frequencies, as compared with unaffected
hosts [9]. Second, gp100-specific T cells in vitiligoaffected mice developed an overwhelmingly effector
memory (TEM) phenotype, in contrast to a predominantly
central memory (TCM) phenotype in hosts without vitiligo
[9]. In accordance with their TEM phenotype, gp100specific T cells in mice with vitiligo homed preferentially
to peripheral tissue sites. Although chronically activated,
these cells did not display phenotypic or functional signs
of exhaustion, even more than one year after priming [9].
This non-exhausted phenotype was not expected, as it had
long been speculated that exposure to self-antigen would
drive memory T cells to exhaustion and deletion, which is
observed in chronic viral infection models [74]. However,
vitiligo-affected mice also exclusively maintained longterm CD8 T cell-mediated protection against a secondary
B16 tumor challenge, confirming the protective function
of these cells [9]. Studies comparing memory CD8 T cell
populations for adoptive T cell therapy had previously
led to the hypothesis that TCM cells are more potent antitumor effectors than TEM cells [67]. Our studies show that
large populations of non-exhausted TEM cells also provide
durable tumor protection— a unique feature of hosts with
autoimmunity.
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Lessons learned from melanocyte-deficient mice

in Wsh mice by exogenous supplementation of gp100
antigen, confirming that melanocyte antigen is required
for the maintenance of T cell memory [9]. These studies
establish that melanocyte antigens liberated by vitiligo
drive the maintenance of a unique, functional, antigendependent memory T cell response to melanoma [9]. The
fact that vitiligo directly sustains immune responses to
melanoma provides new insight into a phenomenon that
has long been observed in the clinic and the laboratory.

Our comparison of T cell memory in vitiligo-affected
and unaffected mice demonstrated a clear correlation
between autoimmunity and the maintenance of robust,
protective, T cell responses to melanoma. However, these
studies did not address whether vitiligo directly contributed
to T cell immunity. To specifically answer this question,
we established the Wsh mouse model of melanocyte
deficiency as a model of vitiligo insufficiency (Figure 2)
[75]. Due to a mutation in the regulatory region of c-kit,
Wsh mice are overwhelmingly melanocyte deficient, and
appear almost completely white, with the exception of the
retina [75, 76]. Traditionally used as a mast-cell deficient
model, Wsh mice had not been previously employed as a
model of vitiligo insufficiency [76]. However, these mice
have proven to be a useful tool to investigate the role of
melanocyte destruction in the maintenance of melanoma
T cell responses to melanoma.
Using the Wsh model, we have recently found that
the absence of melanocytes impairs the development of
T cell memory to melanoma [9]. Our data show that Wsh
mice prime gp100-specific CD8 T cells that are equivalent
in frequency and phenotype to wild-type hosts. However,
they are unable to develop the robust effector memory
T cell responses that characterize hosts with vitiligo [9].
Instead, melanocyte-deficient mice develop small, TCM
populations, similar to those in vitiligo-unaffected wildtype mice [9]. Moreover, when gp100-specific CD8 T
cells were first primed in tumor-bearing Wsh mice, and
then adoptively transferred into melanocyte-sufficient
mice with vitiligo, the unique TEM phenotype and homing
function of these T cells was restored [9]. Thus, the
fate of melanoma antigen-specific CD8 T cells was not
pre-determined at priming, but rather was altered by
exposure to melanocyte destruction. Additionally, robust
populations of gp100-specific TEM cells could be rescued

Shared melanoma/melanocyte antigens vs. tumorspecific antigens
While we have emphasized the role of autoimmunity
in maintaining anti-tumor immunity, it is important to
differentiate between responses directed against shared
melanoma/melanocyte antigens and those directed against
tumor-specific antigens. In melanoma patients, CD8 T cell
epitopes from NY-ESO-1 [2], MAGE [2], and BRAFV600E
[77], have been reported, and may represent natural
tumor-specific antigens that can be targeted for protective
anti-tumor immunity without vitiligo. Accordingly, our
laboratory has recently shown that protective memory
CD8 T cell responses to B16 melanoma can be generated
in the complete absence of vitiligo if rejection antigens are
tumor-specific [78]. In B16 tumor-bearing mice treated by
surgery and a stimulatory mAb against the glucocorticoidinduced TNFR family-related receptor (GITR), we found
that protective T cell responses are preferentially directed
against tumor-specific antigens [78]. This was evidenced
by the fact that mice avidly rejected B16 melanoma rechallenge, but demonstrated no cross-protection against
JBRH melanoma. Accordingly, GITR stimulation did
not break T cell tolerance to melanocyte differentiation
antigens, or induce vitiligo, although it resulted in highavidity T cell responses against B16 tumor-expressed
ovalbumin (OVA) as a model tumor-specific antigen [78].
The mechanisms whereby GITR stimulation skews T
cell immunity to tumor-specific antigens remains under
investigation, however these data provide evidence that
protective CD8 memory T cell responses to melanoma
can be generated in the absence of autoimmunity.
There is also evidence that T cell memory to tumorspecific antigens more closely mimics classical memory
T cell responses described in acute viral infection models
[79]. In studies investigating CD8 T cell responses
generated by Treg depletion and surgery in mice bearing
B16-OVA tumors, we found that OVA-specific CD8 T
cells develop into a small but functional memory T cell
population, with a predominantly TCM phenotype [9]. This
was true regardless of the vitiligo status of the host [9].
Generating such long-lived T cell memory against tumorspecific antigens will be particularly important for tumors
of essential organs, such as the liver or pancreas, where
autoimmune responses cannot be tolerated.
For melanoma, we propose that two major types

Figure 2: Wsh mice as a model of vitiligo insufficiency.
A vitiligo affected mouse (left) and a Wsh mouse (right).
www.impactjournals.com/oncotarget
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of protective memory T cell responses can be generated,
depending on the antigen-specificity of the response
(Figure 3). The first type, directed against shared
melanoma/melanocyte antigens, has a more stringent set
of requirements for T cell priming. However, if T cells
efficiently mediate tumor rejection and induce vitiligo,
they will develop into a unique, functional memory T
cell response that relies on melanocyte destruction for
its ongoing maintenance. Alternatively, a second type of
memory, directed against tumor-specific antigens, can be
likened to T cell responses against foreign antigens. During
the effector phase, these T cells will target melanoma
cells without killing healthy melanocytes. Subsequently,
following melanoma clearance, they develop into
classical, antigen-independent T cell memory. As both
types of memory would be expected to provide durable

Factors Driving
Priming

CD8 T cell
Specificity

Inflammation

(systemic and/or skin)

Vitiligo has been more difficult to generate in
humans than in mice, although certain immunotherapies
clearly promote its development. In a large retrospective
analysis of 374 metastatic melanoma patients treated with
high-dose IL-2, a total of 84 patients (22%) developed
treatment-related vitiligo, although in patients with
objective clinical responses the incidence of vitiligo was
nearly 50% [8]. Another study found that IL-2 and GM-

Effector Phase

Unique TEM
phenotype
Large
population size
Antigendependent

Vitiligo

Antigen

Memory Phase
Characteristics

TOLERANCE

Cytokines

SHEDDING NEW LIGHT ON THERAPYINDUCED VITILIGO IN PATIENTS

Tumor/self
antigens

Altered Antigen
TReg Depletion

protection against melanoma, such a model can explain
how long-term immunity to cancer can be achieved either
in the presence or absence of autoimmunity.

Tumor-specific
antigens

Characteristics
Classical TCM
phenotype

TReg Depletion
Cytokines

Small
population size

Inflammation

CD8 T cell

Dying
Melanoma cell melanoma cell
Dying
Melanocyte
melanocyte

Non-exhausted

Antigenindependent

No Vitiligo

Non-exhausted

Figure 3: Pathways to protective memory CD8 T cell responses to melanoma. (Top) Generation of CD8 T cell responses to

shared melanoma/melanocyte antigens. Factors that contribute to priming of are listed at left. One or more of these factors leads to the
breaking of tolerance (indicated by red line), resulting in effective primary CD8 T cell responses against melanoma that cross-react against
healthy melanocytes and induce vitiligo during the effector phase. Ongoing melanocyte destruction provides antigen to support the memory
phase of the response; unique characteristics of vitiligo-dependent memory T cells are indicated at right. (Bottom) Generation of CD8 T
cell responses against tumor-specific antigens expressed by melanoma. Factors contributing to priming are listed at left; there is no need to
overcome tolerance to generate primary CD8 T cell responses against tumor-specific antigens. In the effector phase, CD8 T cells directed
against tumor-specific antigens kill melanoma cells but do not cross-react with melanocytes, therefore vitiligo does not occur. During the
memory phase, CD8 T cells directed against tumor specific antigens possess classical memory T cell characteristics, indicated at right.
www.impactjournals.com/oncotarget
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CSF maintenance therapy induced vitiligo in a striking 43%
of patients (21 out of 49), who demonstrated significantly
enhanced survival as compared with unaffected patients
[6]. Combination of high-dose IL-2 with CD8 adoptive
T cell therapy (ACT) and lymphodepleting chemotherapy
has received much attention in recent years. In a small
study, this ACT regimen induced vitiligo in 5 out of 13
melanoma patients, all of whom demonstrated significant
tumor regression [7]. More recent data demonstrate that
myeloablative regimens further improve the efficacy of
ACT, resulting in a 70% metastatic melanoma response
rate [80], however, the effects of such therapy on vitiligo
development have not yet been reported. These studies
demonstrate that high rates of vitiligo can be achieved
with certain types of immunotherapy, and may further
imply that therapy-induced vitiligo promotes protective
immune responses to melanoma. Future investigation
of melanoma/melanocyte antigen-specific T cells in
surviving vitiligo-affected and unaffected patients should
provide further insights into the types of T cell memory
that mediate tumor protection in humans.
Vitiligo induction as a crucial component of
melanoma tumor immunotherapy is by no means a new
concept. In 1977, Lerner and Nordlund suggested that
vitiligo should be induced in patients after resection
of primary melanoma, and further proposed the use of
melanocytotoxic compounds such as monobenzone
[19, 81]. Monobenzone therapy was in fact used on a
small cohort of late-stage melanoma patients in 1986
and, while 11 out of 17 treated patients had complete
responses, their vitiligo status was not reported [82]. No
further trials have investigated the therapeutic efficacy
of vitiligo induction in melanoma patients, however
several groups have resurrected the hypothesis as of
late [30, 36, 61, 83]. Recent in vitro studies by van den
Boorn and colleagues have elucidated the mechanism by
which monobenzone results in human melanocyte cell
death and the downstream initiation of anti-melanocyte
CD8 T cell responses [60]. These studies support animal
data from the same group, where monobenzone and TLR
agonist treatment of mice with established B16 tumors
required CD8 T cells for efficacy [61]. Other methods of
specifically targeting melanocytes for destruction, such
as anti-TRP-1 mAb [84] and tert-butyl-phenol (TBP)
[83] could be used similarly, or as an adjuvant therapy
following surgical tumor removal. New mechanistic
insights into the importance of vitiligo clearly support
future investigation of vitiligo induction as a component
of combination melanoma immunotherapies.
Finally, the development of melanocyte-unrelated
autoimmune disease in melanoma patients warrants
comment. In melanoma patients receiving adjuvant IFN-α
therapy, generalized autoimmunity has been reported to
correlate with clinical responses [85]. Similarly, following
treatment with ipilimumab (anti-CTLA-4), over a third
of total responding patients developed autoimmunity,
www.impactjournals.com/oncotarget

although not limited to vitiligo [11]. While there is no
evidence that melanocyte-unrelated autoimmune disease
can directly promote melanoma-specific T cell responses,
generalized autoimmunity may provide particular
inflammatory and/or danger signals that help to overcome
tolerance to self-antigens expressed by tumors. Specific
attributes of tissue-specific and non-specific autoimmune
disease that contribute to anti-tumor immunity are only
beginning to be understood, and will require future
investigation.

CONCLUSIONS
The development of vitiligo clearly portends
enhanced survival in melanoma patients, and recent
experimental data has now provided a new understanding
of this phenomenon. Vitiligo is still reported as an ‘adverse
event’ during clinical trial evaluation [86], however, this
thinking is now shifting. Future studies will be necessary
to address whether durable clinical responses in melanoma
patients (e.g. those receiving adoptive T cell therapies) are
supported by the concurrent progression of vitiligo. More
broadly, given the potential efficacy of therapies that target
shared tumor/self antigens, we propose that driving tissuespecific autoimmune disease is both feasible and desirable
for tumors of non-essential organs (e.g. melanoma,
breast, prostate, and ovarian cancer). In conjunction with
promising new cancer therapies, harnessing the supportive
role of autoimmunity may tip the scales against tumor
growth and in favor of lasting anti-tumor immunity.
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